Table 1.
Comparison of baseline data between the two groups.
| Information | Control group (n = 47) | Observation group (n = 47) | t/χ2 | P |
|---|---|---|---|---|
| Gender (male/female) | 28/19 | 30/17 | 0.180 | 0.671 |
| Age | 36~77 (58.09 ± 7.73) | 35~78 (59.14 ± 8.25) | 0.637 | 0.526 |
| BMI (kg/m2) | 17~28 (22.91 ± 1.76) | 17~28 (23.11 ± 2.08) | 0.503 | 0.616 |
| Tumor diameter (cm) | 0.5~2.0 (1.68 ± 0.15) | 0.5~2.0 (1.64 ± 0.16) | 1.250 | 0.214 |
| TNM staging | ||||
| 0 stage | 2 (4.26) | 1 (2.13) | 0.474 | 0.789 |
| IA stage | 39 (82.98) | 41 (87.23) | ||
| IB stage | 6 (12.77) | 5 (10.64) | ||
| Pathology | ||||
| Adenocarcinoma | 36 (76.60) | 38 (80.85) | 0.446 | 0.800 |
| Squamous carcinoma | 9 (19.15) | 8 (17.02) | ||
| Others | 2 (4.26) | 1 (2.13) | ||
| Complications | ||||
| Hypertension | 3 (6.38) | 1 (2.13) | 1.044 | 0.307 |
| Diabetes | 2 (4.26) | 1 (2.13) | 0.001 | 1.000 |
| Coronary heart disease | 1 (2.13) | 2 (4.26) | 0.001 | 1.000 |
BMI: body mass index; TNM: tumor, nodes, and metastases.